Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 18/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 12/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14830562 | 1.00 | CYP17A1 (0.42) | CYP17A1CYP1A2CYP11B1CYP11B2GPBAR1 | |
| SCHEMBL14831195 | 0.90 | CYP17A1 (0.46) | CYP17A1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14831196 | 0.90 | CYP17A1 (0.46) | CYP17A1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14830650 | 0.84 | CYP17A1 (0.43) | CYP17A1CYP1A2GPBAR1 | |
| SCHEMBL14830912 | 0.77 | CYP17A1 (0.39) | CYP17A1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14830911 | 0.77 | CYP17A1 (0.39) | CYP17A1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL14832000 | 0.73 | CYP17A1 (0.46) | CYP17A1CYP1A2CYP11B1CYP11B2 | |
| SCHEMBL30761095 | 0.71 | GRM5 (0.50) | — | |
| SCHEMBL14830968 | 0.70 | CYP17A1 (0.36) | CYP17A1CYP1A2CYP11B1 | |
| SCHEMBL14830969 | 0.70 | CYP17A1 (0.36) | CYP17A1CYP1A2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| EP-2760870-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP1A2, CYP3A43, CYP4A22 | CYP17A1 35/4885CYP1A2 1/4885CYP11B1 19/4885 |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885CYP1A2 2/4885CYP11B1 16/4885 |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885CYP1A2 2/4885CYP11B1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.